ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Botanical/Drug Interactions in HIV: Glucuronidation

This study has been completed.

Sponsored by: National Center for Complementary and Alternative Medicine (NCCAM)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00065741
  Purpose

A series of clinical studies will be conducted in normal, healthy adult volunteers to evaluate the potential for alterations in the pharmacokinetics of anti HIV drugs when botanicals/nutriceuticals are given concurrently via the oral route. Both the drugs and botanicals are known to rely upon or to modulate, respectively, metabolism via glucuronidation.


Condition Intervention Phase
HIV Seronegativity
Drug: silymarin
Phase I

MedlinePlus related topics:   AIDS   

Drug Information available for:   Zidovudine    Abacavir    Abacavir sulfate    Mycophenolate Mofetil    Mycophenolate mofetil hydrochloride    Silymarin   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Prevention, Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacokinetics Study
Official Title:   Botanical/Drug Interactions in HIV: Glucuronidation

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment:   60
Study Start Date:   September 2003
Estimated Study Completion Date:   March 2006

Detailed Description:

As per Brief Summary

  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion criteria:

  • Absence of HIV-1 infections

    • Body mass index less than or equal to 30 kg/m2 and weigh at least 50 kg.
  • Laboratory values obtained within 7 days of study entry within normal range for healthy volunteers.
  • Able to be compliant with dosing schedules and diary record keeping.
  • Able to follow dietary restrictions associated with the protocol.
  • Ability and willingness to provide informed consent
  • All women of reproductive potential must have a negative pregnancy test
  • All women of reproductive potential to use contraception methods as defined by protocol
  • All study subjects (male and female) must agree to not participate in a conception process

Exclusion Criteria:

  • History of any acute or chronic illness that requires current medical therapy including active gastrointestinal conditions that might interfere with drug absorption.
  • History of hepatic, renal, cardiovascular, gastrointestinal diseases.
  • Current gastrointestinal disturbance.
  • Receipt of any prescribed or over the counter medication or ingested CAM during the 30 days prior to study entry except: Over the counter acetaminophen or ibuprofen at doses not exceeding package labeling guidelines.
  • Any medical condition that, in the opinion of the investigator, would interfere with the subject’s ability to participate in this protocol.
  • Pregnancy or breastfeeding.
  • Allergy/sensitivity to study agent(s) or their formulations.
  • Active drug or alcohol abuse or dependence, which in the opinion of the investigator would interfere with adherence to study requirements or would endanger the subject’s health while on study.
  • Before entering the study, subjects must agree not to consume alcohol for 48 hours prior to PK sampling days.
  • Participation in any investigational drug studies within 30 days prior to study entry and during study.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065741

Locations
United States, North Carolina
General Clinical Research Center, Univiversity Of North Carolina at Chapel Hill    
      Chapel Hill, North Carolina, United States, 27599

Sponsors and Collaborators

Investigators
Principal Investigator:     Philip C Smith, PhD     School of Pharmacy, UNC Chapel Hill    
Study Director:     David A Wohl, MD     Department of Medicine, AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill    
  More Information


Study ID Numbers:   R21 AT001376-01A1
First Received:   July 31, 2003
Last Updated:   March 21, 2007
ClinicalTrials.gov Identifier:   NCT00065741
Health Authority:   United States: Federal Government

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
Milk thistle  
silymarin  
piperine  
glucarate  
zidovudine  
abacavir  
mycophenolate mofetil  
HIV
pharmacokinetics
interaction
glucuronidation
Healthy
Complementary Therapies

Study placed in the following topic categories:
HIV Infections
Acquired Immunodeficiency Syndrome
Mycophenolate mofetil
Silymarin
Zidovudine
Healthy
Abacavir

Additional relevant MeSH terms:
Antioxidants
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers